Mia Husić

Mia Husić

Auto-generated profile, based on publicly available information

Mia Husić

Centre for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2018 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
DHD. W. Hogg
D. W. Hogg
YCY. Chen
Y. Chen
ADA. L. D'AQuila
A. L. D'AQuila
MXM. Xu
M. Xu
MHM. Husić
M. Husić
DLD. A. Lovejoy
D. A. Lovejoy

1 January 2018
Verified
Book Chapter
Closed access
DHDavid W. Hogg
David W. Hogg
MHMia Husic
Mia Husic
DLDavid A. Lovejoy
David A. Lovejoy

29 March 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SMSuluxan Mohanraj
Suluxan Mohanraj
JDJ. Javier Díaz-Mejía
J. Javier Díaz-Mejía
MPMartin D. Pham
Martin D. Pham
HEHillary Elrick
Hillary Elrick
MHMia Husić
Mia Husić
TPTrevor J Pugh
Trevor J Pugh
CReSCENT: CanceR Single Cell ExpressioN Toolkit ( https://crescent.cloud ), is an intuitive and scalable web portal incorporating a containerized pipeline execution engine for standardized analysis of single-cell RNA sequencing (scRNA-seq) data. While scRNA-seq data for tumour specimens are readily generated, subsequent analysis requires high-performance computing infrastructure and user expertise to build analysis pipelines and tailor interpretation for cancer biology. CReSCENT uses public data sets and preconfigured pipelines that are accessible to computational biology non-experts and are user-editable to allow optimization, comparison, and reanalysis for specific experiments. Users can also upload their own scRNA-seq data for analysis and results can be kept private or shared with other users.

30 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
YJYue Jiang
Yue Jiang
MAMichael J. Apostolides
Michael J. Apostolides
MHMia Husić
Mia Husić
RSRobert Siddaway
Robert Siddaway
MYMan Yu
Man Yu
MBMichael Brudno
Michael Brudno
Recent advancements in high throughput sequencing analysis have enabled the characterization of cancer-driving fusions, improving our understanding of cancer development. Most fusion calling methods, however, examine either RNA or DNA information alone and are limited to a rigid definition of what constitutes a fusion. For this study we developed a pipeline that incorporates several fusion calling methods and considers both RNA and DNA to capture a more complete representation of the tumour fusion landscape. Interestingly, most of the fusions we identified were specific to RNA, with no evidence of corresponding genomic restructuring. Further, while the average total number of fusions in tumour and normal brain tissue samples is comparable, their overall fusion profiles vary significantly. Tumours have an over-representation of fusions occurring between coding genes, whereas fusions involving intergenic or non-coding regions comprised the vast majority of those in normals. Tumours were also more abundant in unique, sample-specific fusions compared to normals, though several fusions exhibited strong recurrence in the tumour type examined (diffuse intrinsic pontine glioma; DIPG) and were absent from both normal tissues and other cancers. Intriguingly, tumours also show broad up- or down-regulation of spliceosomal gene expression, which significantly correlates with fusion number (p=0.007). Our results show that RNA-specific fusions are abundant in both tumour and normal tissue and are associated with spliceosomal gene dysregulation. RNA-specific fusions should be considered as a potential mechanism that may contribute to cancer formation initiation and maintenance alongside more traditional structural events.

20 September 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
MAMichael Apostolides
Michael Apostolides
YJYue Jiang
Yue Jiang
MHMia Husić
Mia Husić
RSRobert Siddaway
Robert Siddaway
CHCynthia Hawkins
Cynthia Hawkins
ARArun K. Ramani
Arun K. Ramani
Motivation Gene fusions are often associated with cancer, yet current fusion detection tools vary in their calling approaches, making selecting the right tool challenging. Ensemble fusion calling techniques appear promising; however, current options have limited accessibility and function. Results MetaFusion is a flexible meta-calling tool that amalgamates the outputs from any number of fusion callers. Results from individual callers are converted into Common Fusion Format, a new file type that standardizes outputs from callers. Calls are then annotated, merged using graph clustering, filtered and ranked to provide a final output of high confidence candidates. MetaFusion consistently outperformed individual callers with respect to recall and precision on real and simulated datasets, achieving up to 100% precision. Thus, an ensemble calling approach is imperative for high confidence results. MetaFusion also labels fusions found in databases using the FusionAnnotator package, and is provided with a benchmarking toolkit to calibrate new callers. Availability MetaFusion is freely available at https://github.com/ccmbioinfo/MetaFusion Contact arun.ramani{at}sickkids.ca